Inhibition of Phosphorylated Alpha-Synuclein Aggregation by Synthetic Protein Mimetics and Foldamers
- 24 December 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (2) , 152-160
Abstract
The formation of Lewy bodies (LB) is a pathological hallmark for synucleinopathies, which is an umbrella term for many diseases, including Parkinson's disease, Lewy body dementia, and multiple system atrophy. One of the main components of LB is the aggregates of phosphorylated modification of α-Synuclein at residue 129 (αS-129), a neuronal protein expressed in the dopaminergic neurons in the brain. There are equivocal results about the role of αS-129, suggesting its involvement in both potentiating pathology and a functional role to rescue pathology. Regardless, a potential therapeutic strategy for LB-based pathologies could be the identification of inhibitors of both αS and αS-129 aggregation. However, to the best of our knowledge, there are no reports of ligands that can potently inhibit the aggregation of αS-129. Our group has recently identified potent antagonists of αS aggregation based on the oligopyridylamide (synthetic protein mimetics) and oligoquinoline (foldamers) scaffolds. Both ligands were potent antagonists of αS aggregation-mediated disease phenotypes in various PD models. Here, we tested both ligands against αS-129 aggregation and the coaggregation of αS and αS-129 (αS/αS-129). Both ligands were potent antagonists of αS-129 aggregation and coaggregation of αS/αS-129 in biophysical and cellular models of PD. Both ligands rescued cell toxicity mediated by the coaggregation of αS/αS-129. To the best of our knowledge, these are the first ligands that potently inhibit the major component of LB. This finding will aid in the development of therapeutic insights into aggregation-related synucleinopathies.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (1R61NS137824-01)
- American Parkinson's Disease Foundation (R79)
- University of Denver
- Parkinson's Foundation (PF-SF-JFA-1046268)
- Knoebel Institute for Healthy Aging
This publication has 57 references indexed in Scilit:
- Ultrastructural and biochemical classification of pathogenic tau, α-synuclein and TDP-43Acta Neuropathologica, 2022
- α-Synuclein misfolding and aggregation: Implications in Parkinson’s disease pathogenesisBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2019
- Expression and Purification of Untagged α-Synuclein2019
- Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal FluidJAMA Neurology, 2017
- Targeting Protein-Protein Interactions for Drug Discovery2015
- Role of C‐terminal negative charges and tyrosine residues in fibril formation of α‐synucleinBrain and Behavior, 2012
- α-Synuclein misfolding and Parkinson's diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- Clinical progression in Parkinson disease and the neurobiology of axonsAnnals of Neurology, 2010
- Synthetic α‐Helix Mimetics as Agonists and Antagonists of Islet Amyloid Polypeptide AggregationAngewandte Chemie International Edition, 2010
- Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solutionProtein Science, 1993